Neurodegenerative diseases are among the biggest health issues we face presently. In Germany, about 1.8 million people are living with dementia, and that number is likely to rise to 2.7 million by 2050. As people are living longer and more people are developing these conditions, it’s putting a lot of pressure on patients, their loved ones, and the healthcare system. Even though there have been some advances in research, there’s still not enough effective treatment to help reduce symptoms and improve the lives of those affected.
Health Technology Insights: LEO Pharma Showcases New Data at 2025 Dermatology Event
Because of this, there is a growing need for new treatments that are backed by solid clinical evidence. Cannabis-based medicines, especially full-spectrum extracts, are getting attention because they may help with the brain processes involved in these diseases. To look into this more closely, the NEUROBIS study has started in Italy. This Phase II clinical trial is randomized, double-blind, and placebo-controlled, which means it will test both the safety and how much these medicines can improve the quality of life for people with neurodegenerative conditions.
The three-year study was approved and funded by the Italian Ministry of Health under the 2022 Ricerca Finalizzata program. It will involve 180 participants diagnosed with amyotrophic lateral sclerosis (ALS), Parkinson’s disease, or Alzheimer’s disease. The start of the first patient’s enrollment is a major step in moving forward with the use of cannabis-based treatments for these conditions.
Health Technology Insights: MindWalk Names R. Scott Areglado as New CFO
The trial is being directed by Professor Letizia Mazzini, a respected neurologist and researcher with over 30 years of experience in studying neurodegenerative diseases. She heads the ALS Center in Novara and is a leading expert in motor neuron diseases in Italy. Professor Mazzini expressed pride in the study’s start and said the team, working with Avextra, plans to use medical expertise and innovation to explore the potential of medical cannabis as a helpful treatment for patients with these disorders. She added that the main goal is to create strong scientific evidence that can result in real clinical benefits.
Avextra‘s CEO, Bernhard Babel, noted that the NEUROBIS study is a major milestone in the company’s clinical research plan. He explained that Avextra’s full-spectrum cannabis extract, made with strict quality and consistency standards, will be key in the trial. Babel highlighted that this project shows Avextra’s ongoing commitment to improving patients’ lives and offering scientifically supported treatment choices in the field of neurodegenerative care.
Health Technology Insights: Hyperfine Enrolls First Patients in PRISM PMR Study
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- GlobeNewswire
